Literature DB >> 30242383

Treatment of Mucous Membrane Pemphigoid With Janus Kinase Inhibitor Baricitinib.

Stephanie Sarny1,2, Miriam Hucke3, Yosuf El-Shabrawi1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30242383     DOI： 10.1001/jamaophthalmol.2018.3789

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN： 2168-6165            Impact factor:   7.389


× No keyword cloud information.
  9 in total

Review 1.  Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review.

Authors:  Chang-Yu Hsieh; Tsen-Fang Tsai
Journal:  Am J Clin Dermatol       Date:  2022-08-14       Impact factor: 6.233

2.  Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report.

Authors:  Birao Fan; Mingyue Wang
Journal:  Acta Derm Venereol       Date:  2022-06-09       Impact factor: 3.875

Review 3.  [Pharmacology of Janus kinase inhibitors].

Authors:  F Solimani; F J Hilke; K Ghoreschi
Journal:  Hautarzt       Date:  2019-12       Impact factor: 0.751

4.  Tofacitinib for refractory ocular mucous membrane pemphigoid.

Authors:  Hayley James; Grace L Paley; Richard Brasington; Philip L Custer; Todd P Margolis; Michael A Paley
Journal:  Am J Ophthalmol Case Rep       Date:  2021-04-21

5.  Tofacitinib for refractory uveitis and scleritis.

Authors:  Michael A Paley; Humeyra Karacal; P Kumar Rao; Todd P Margolis; Jonathan J Miner
Journal:  Am J Ophthalmol Case Rep       Date:  2018-12-04

Review 6.  Emerging Topical and Systemic JAK Inhibitors in Dermatology.

Authors:  Farzan Solimani; Katharina Meier; Kamran Ghoreschi
Journal:  Front Immunol       Date:  2019-12-03       Impact factor: 7.561

7.  Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review.

Authors:  Ji Wen; Huifang Hu; Menglin Chen; Hang Yang; Yi Zhao; Yi Liu
Journal:  J Immunol Res       Date:  2021-12-20       Impact factor: 4.818

8.  Successful treatment of recalcitrant mucous membrane pemphigoid with multisystem involvement with baricitinib and methotrexate.

Authors:  Kevin M Burningham; Jennifer Cao; Arturo R Dominguez
Journal:  JAAD Case Rep       Date:  2022-07-16

9.  Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases.

Authors:  Saeedeh Ghorbanalipoor; Shirin Emtenani; Melissa Parker; Mayumi Kamaguchi; Colin Osterloh; Manuela Pigors; Natalie Gross; Stanislav Khil'chenko; Anika Kasprick; Sabrina Patzelt; Diana Wortmann; Ibrahim O Ibrahim; Kentaro Izumi; Stephanie Goletz; Katharina Boch; Kathrin Kalies; Katja Bieber; Paul Smith; Enno Schmidt; Ralf J Ludwig
Journal:  Front Immunol       Date:  2022-09-28       Impact factor: 8.786
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.